Glycemic Lowering Effectiveness of Linagliptin/Metformin in Type 2 Diabetes by Age, Body Mass Index, and Renal Function

Li-Ching Li ； Chenyi Chu ； Chien-Ning Huang ； Edy Kornelius ； Shih-Chang Lo ； Yi-Sun Yang

《Formosan Journal of Endocrinology and Metabolism》 13卷2期 (2022/12) Pp. 74-82

https://doi.org/10.6856/FJEM.202212_13(2).0010

摘要

Aims: Combination therapy is an important part of the intensification clinical management of type 2 diabetes mellitus (T2D). Using fixed-dose combination (FDC) tablets could improve adherence in this population. This study aimed to assess the glucose lowering efficacy efficacy of using fixed-dose combination of linagliptin/metformin during intensification therapy in patients with suboptimal glycemic control. Methods: This was a non-interventional retrospective cohort study using data in the electronic medical record database from adults with T2D adding FDC of linagliptin plus metformin with glycated hemoglobin (HbA1c) more than 7%. Date of the first FDC of linagliptin plus metformin prescription was the index date. Outcomes included change in HbA1c during the 3-12 months following FDC of linagliptin plus metformin initiation. Analyses of age, renal function, body mass index were conducted. Results: Overall, 831 patients were included. Mean pre-index HbA1c value was 7.84%. Patients adding FDC of linagliptin plus metformin had an average HbA1c reduction of 0.48% and 0.64 % at 3, 12 months, respectively. Fasting plasma glucose was decreased by 10.9 mg/dL and 17.9 mg/dL at 3, 12 months respectively. Change of body weight was neutral for 12-month follow-up. The therapeutic effect regarding HbA1c reduction was independent of age, creatinine level, and body mass index. Conclusions: These results support the glucose lowering effectiveness of FDC of linagliptin plus metformin across age, body mass index, and renal function categories among a real-world population of adults with T2D with suboptimal glycemic control.

關鍵字

type 2 diabetes mellitus ； linagliptin ； metformin